Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
115 hedge funds and large institutions have $271M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 25 closing their positions.
217% more call options, than puts
Call options by funds: $570K | Put options by funds: $180K
26% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 35
11% more capital invested
Capital invested by funds: $243M → $271M (+$27.7M)
12% less funds holding
Funds holding: 130 → 115 (-15)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
56% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$12.4M |
| 2 |
RI
RTW Investments
New York
|
+$8.65M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$3.63M |
| 4 |
Goldman Sachs
New York
|
+$3.16M |
| 5 |
O
OrbiMed
New York
|
+$3.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$10.8M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$3.3M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.91M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.6M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2.38M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TI
126
Trexquant Investment
Stamford,
Connecticut
| – | -$227K | -33,322 | Closed |
|
|
XT
127
XTX Topco
George Town,
Cayman Islands
| – | -$204K | -29,928 | Closed |
|
|
ECM
128
ExodusPoint Capital Management
New York
| – | -$177K | -26,064 | Closed |
|
|
EGM
129
Engineers Gate Manager
New York
| – | -$167K | -24,500 | Closed |
|
|
HF
130
HRT Financial
New York
| – | -$151K | -22,255 | Closed |
|
|
MGB
131
Mass General Brigham
Somerville,
Massachusetts
| – | -$131K | -19,291 | Closed |
|
|
HSA
132
Hussman Strategic Advisors
Ellicott City,
Maryland
| – | -$105K | -15,500 | Closed |
|
|
PP
133
PDT Partners
New York
| – | -$102K | -15,009 | Closed |
|
134
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$75K | -12,108 | Closed |
|
|
HW
135
Hancock Whitney
Gulfport,
Mississippi
| – | -$79K | -11,664 | Closed |
|
|
PCM
136
Prelude Capital Management
New York
| – | -$78K | -11,400 | Closed |
|
|
PHK
137
Point72 Hong Kong
Hong Kong
| – | -$31K | -4,606 | Closed |
|
|
MCM
138
MV Capital Management
Bethesda,
Maryland
| – | -$3K | -500 | Closed |
|
|
EI
139
Ellevest Inc
New York
| – | -$118 | -19 | -56% |
|
JNCE Hedge Fund Activity: Q3 2021 in Review
115 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q3 2021, worth a combined $271M — up 11% from $243M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of JNCE and 11 opened new positions — a net loss of 14 holders — while 35 trimmed existing stakes and 44 added.
The largest buyer was Logos Global Management, opening a new position worth an estimated $12.4M. The largest seller was TRV GP II, cutting an estimated $10.8M.
- 115 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q3 2021, down from 130 in Q2 2021.
- Funds reported $271M of Jounce Therapeutics, Inc. Common Stock stock for Q3 2021, up 11% quarter-over-quarter.
- 11 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q3 2021 and 25 closed out, a net change of -14 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q3 2021 was Logos Global Management, an estimated $12.4M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q3 2021 was TRV GP II, an estimated $10.8M sold.
Based on aggregated 13F filings for Q3 2021.